Educational Symposium
Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Kidney Disease
October 26, 2024 | 12:45 PM - 01:45 PM
Location: Marriott Grand Ballroom 13, Marriott Marquis
Session Description
Agonists of the glucagon-like peptide-1 receptor (GLP-1 RAs) are becoming an important player in diabetes itself, and in diabetic kidney disease for kidney and cardiovascular outcomes. Rapidly emerging data from randomized clinical trials offer a more and more granular view of the drugs' effectiveness and advance our understanding of their mechanism of action.
Support is provided by an educational grant from Novo Nordisk.
Learning Objective(s)
- Outline recent advances in clinical trials of GLP-1 RAs in diabetic kidney disease for kidney and cardiovascular outcomes
- Describe the mechanisms of action of GLP-1 RAs in diabetic complications
Learning Pathway(s)
- Diabetic Kidney Disease
- CKD Non-Dialysis
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- GLP-1 RAs in Diabetic Kidney Disease: Focus on Kidney Outcomes
12:55 PM - 01:15 PM
- GLP-1 RAs: On the Mechanisms of Renoprotection
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM